View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Dec. 20 (HealthDay News) -- In pregnant women with asthma, the use of inhaled glucocorticoids does not increase the risk of most pediatric diseases in the offspring, though it may be a risk factor for endocrine and metabolic disorders, according to research published online Dec. 16 in the American Journal of Respiratory and Critical Care Medicine.
Marion Tegethoff, Ph.D., of the University of Basel in Switzerland, and colleagues analyzed prospective data from 4,083 mother-child pairs (births between 1996 and 2002) in the Danish National Birth Cohort. Logistical regression analyses for each ICD-10 diagnosis category were used to estimate associations between prenatal use of inhaled glucocorticoids for asthma (1231/4083) and childhood diseases in the offspring (median age at end of follow-up, 6.1 years).
According to the researchers, inhaled glucocorticoid use for asthma during pregnancy was not associated with increases in risk for most childhood diseases, except metabolic and endocrine disorders (hazard ratio, 1.84). The analysis was repeated for the subgroup that only used budesonide (79.9 percent of treatment subgroup) and similar results were found.
"Regarding most disease categories, data are reassuring, supporting the use of inhaled glucocorticoids during pregnancy. In line with animal data, glucocorticoid inhalation during pregnancy may be a risk factor for offspring endocrine and metabolic disturbances, which should be considered further," the authors write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top